What is he best known for?
The fields of study he is best known for:
- Gene
- Cancer
- Internal medicine
Michael Andreeff mostly deals with Cancer research, Leukemia, Myeloid leukemia, Internal medicine and Immunology.
His studies deal with areas such as Apoptosis, Programmed cell death, Stem cell, Bone marrow and Mesenchymal stem cell as well as Cancer research.
His Leukemia research includes elements of Myeloid and Pharmacology.
His study on Myeloid leukemia also encompasses disciplines like
- Progenitor cell, which have a strong connection to CD34,
- Cytogenetics that connect with fields like Bioinformatics.
His Internal medicine research incorporates elements of Gastroenterology, Philadelphia chromosome and Oncology.
He interconnects Granulocyte colony-stimulating factor and Stem cell transplantation for articular cartilage repair in the investigation of issues within Immunology.
His most cited work include:
- Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). (1169 citations)
- Human Bone Marrow–Derived Mesenchymal Stem Cells in the Treatment of Gliomas (894 citations)
- Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia (857 citations)
What are the main themes of his work throughout his whole career to date?
Cancer research, Leukemia, Myeloid leukemia, Internal medicine and Bone marrow are his primary areas of study.
The various areas that Michael Andreeff examines in his Cancer research study include Cell culture, Apoptosis, Immunology, Stem cell and Mesenchymal stem cell.
Michael Andreeff has researched Apoptosis in several fields, including Molecular biology and Cell growth.
His Leukemia research includes themes of Cancer, Haematopoiesis, Myeloid, CD34 and Pharmacology.
His Venetoclax research extends to the thematically linked field of Myeloid leukemia.
As a part of the same scientific study, he usually deals with the Internal medicine, concentrating on Gastroenterology and frequently concerns with Regimen.
He most often published in these fields:
- Cancer research (53.00%)
- Leukemia (37.09%)
- Myeloid leukemia (28.90%)
What were the highlights of his more recent work (between 2016-2021)?
- Cancer research (53.00%)
- Myeloid leukemia (28.90%)
- Leukemia (37.09%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Cancer research, Myeloid leukemia, Leukemia, Internal medicine and Oncology.
His work deals with themes such as Cell culture, Venetoclax, Stem cell, Mesenchymal stem cell and Bone marrow, which intersect with Cancer research.
His Myeloid leukemia study combines topics in areas such as Stromal cell, Haematopoiesis, Myeloid, CD34 and Quizartinib.
His research investigates the link between Leukemia and topics such as Cancer that cross with problems in Lymphoma.
His research in Internal medicine intersects with topics in Gastroenterology and Azacitidine.
His Oncology research is multidisciplinary, relying on both Newly diagnosed, Myelodysplastic syndromes, Nivolumab, Hypomethylating agent and Cohort.
Between 2016 and 2021, his most popular works were:
- Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. (140 citations)
- Long-term outcome of acute promyelocytic leukemia treated with all- trans-retinoic acid, arsenic trioxide, and gemtuzumab (115 citations)
- Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy (91 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
Michael Andreeff spends much of his time researching Myeloid leukemia, Cancer research, Leukemia, Internal medicine and Oncology.
His Myeloid leukemia study also includes fields such as
- Haematopoiesis which is related to area like Immune system,
- Survival analysis that intertwine with fields like Retrospective cohort study and Transplantation.
His studies in Cancer research integrate themes in fields like Protein kinase B, Immunology, Stem cell, PI3K/AKT/mTOR pathway and MAPK/ERK pathway.
His Leukemia study combines topics from a wide range of disciplines, such as Surgery, Myeloid, Progenitor cell, Mesenchymal stem cell and Bone marrow.
His Bone marrow research is multidisciplinary, incorporating elements of Stromal cell, Nivolumab and Adipocyte.
As a part of the same scientific family, Michael Andreeff mostly works in the field of Internal medicine, focusing on Gastroenterology and, on occasion, Chemotherapy, Regimen, Mucositis, Idarubicin and Combination therapy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
